Quarterly Business Update

Period Ending 31 December 2021

ASX Code: ADO

Shares on Issue

1,970 million

CEO

Mr Derek Thomson

Company Secretary

Mr Tim Pritchard

Principal and Registered Office

Unit 4, 26 Brandl St, Eight Mile Plains, Qld 4113, Australia

Telephone

+61 7 3219 0085

Internet

www.anteotech.com

Email

contact@anteotech.com

ABN

75 070 028 625

Key Activities

Activities for the quarter focused on:

Life Sciences – engagement with the Therapeutic Goods Administrator ("TGA") on achieving regulatory approval for Eugenie Reader and SARS-CoV-2 Ag Rapid Antigen Test ("RAT") and ongoing engagement with Australian industry and government bodies on the position of Rapid Antigen testing and domestic manufacturing as well as the progression of European sales and planning.

Energy - commercialisation opportunities for AnteoX, with engagements progressing positively.

Highlights for the Q2 FY22 Quarter Include:

- Validation of scalability of manufacturing at Operon.
- Renewal of AnteoBind contract with Ellume for further five years.
- Strengthening of internal marketing and sales capability through the commencement of Ian Steinhardt in Head of Markets position.
- Positive initial outcomes recorded pairing AnteoX with SBR binders, the market-dominant binder type.
- Receipt of $1,965,463 under the Federal Government's Research & Development (R&D) Tax Incentive Scheme.

Letter to Shareholders

Dear Shareholders

Along with the board, I am pleased to provide you with our quarterly Activities Report.

Markets for rapid antigen testing (RATs) continued to be extremely dynamic during the December '21 quarter.

The Omicron variant caused a high volume of COVID-19 infection across the globe, creating the need for more testing. In Australia, the laboratory-based PCR testing infrastructure buckled under the pressure of increased numbers of infections and Christmas travellers seeking to cross borders with required COVID-19 free test results. In late December, the Australian Federal Government reversed their stance on the use of RATs as a front-line tool for controlling the pandemic. This sudden change in policy caused a supply shortage of RATs, all of which are currently imported, creating further spread of the disease.

The primary issue at hand in relation to the lack of supply of RATs in Australia is the lack of sovereign manufacturing capability. We call upon Federal and State Governments to support the Australian lateral flow In Vitro Diagnostic (IVD) industry to build local manufacturing capability for lateral flow IVD devices.

As a response to the ongoing evolution of variants and a need to ensure test performance standards are maintained, governments worldwide continue to set the quality bar higher by increasing the regulatory requirements for market entry and continued market participation. In Europe, this has manifested in broader adoption of the EU Common List for procurement of RATs in varied segments. In Australia, the TGA has adopted a guidance note from the European Commission's Medical Device Co-ordination Group (MDCG) on the clinical performance evaluation of RATs. The MDCG requirements underpin the new European In Vitro Diagnostic Regulations (IVDR) that focus on test efficacy using prospective sampling in the 0 – 7 days post-onset symptoms range. A prospective trial involves the recruitment of patients for direct harvesting of samples to be tested on the EuGeni platform for SARS-CoV-2 Ag RDT[1].

The TGA has advised us we must add prospective clinical data to support our test performance claims generated using stored samples to align our technical data with the MDCG guidelines. We are currently collecting this data via trials in Australia and Europe, which will also provide the required data set for entry to the EU Common List and IVDR registration.

Operationally the commencement of Ian Steinhardt in the role of Head of Markets added significant skills and expertise to our go-to-market efforts in Australia and Europe. We continued to scale and optimise our manufacturing at Operon and made sound progress in our development of the COVID-19 Flu A/B multiplex tests and Sepsis biomarker tests.

Key business development activities during the quarter included the strengthening of our relationships with State Governments for the supply of EuGeni tests once TGA approved and, importantly, the renewal of the Ellume contract for the ongoing supply of AnteoBind for a further five years.

The Energy team realised a significant milestone during the quarter by proving a stable mixture of AnteoX and SBR binder. This achievement provides a platform for commercialising AnteoX in a segment that uses SBR, the most commonly used binder in the carbon plus silicon active material anode market, the largest segment of the silicon harnessing anode market.

[1] The AnteoTech Antigen Rapid Test detects the SARS-CoV-2 virus that causes the disease called COVID-19

During the current quarter, our primary focus was on fulfilling the articulated TGA requirements to sell the EuGeni SARS-COV-2 RDT in the Australian market. We have developed a high performing product that the Australian population deserves to be able to use.

I look forward to updating you on our progress as we reach key milestones.

Derek Thomson

Chief Executive Officer

Life Sciences

Supporting Scaled Revenue Generation

Our vision for the business is long term – 10 years plus - development of lateral flow tests on the EuGeni platform to detect a range of conditions. To do this we transformed from raw material supplier, and we are using the COVID-19 market opportunities where possible to facilitate the transition.

We have spent time preparing the business to scale revenues and increase market operations.

We have done this to hedge risk and protect long term shareholder value.

In vitro diagnostic (IVD) manufacture is heavily regulated. To operate in chosen markets successfully, organisations must ensure ongoing supply of product of the highest quality and performance. The products must be fully supported by the manufacturer and integrate the support of OEM suppliers, distributors and supply chain organisations. Any questionable aspect of quality or support will risk scrutiny by regulatory authorities whilst in market and this could lead to penalties and / or removal of product from the market. Many organisations close to AnteoTech have been the subject of such scrutiny and been forced to remove product batches or entire products from the market and this has caused the organisation valuable reputational damage that will hinder further developments.

To ensure compliance with regulatory requirements and ensure product quality is maximised, it is best practice to build processes from product development through manufacturing, distribution, product support and market surveillance that are fully integrated. This requires the involvement of all parties in the chain, including, in the case of AnteoTech, distributors around the world, an outsourced manufacturer in Spain and OEM's such as Axxin and others supplying component parts of our product. It also requires the company to develop products aligned to development procedures recognised by regulators. The standard required by regulators to assess adherence to market operations and development is ISO13485. AnteoTech graduated to legal manufacturer level of this standard in September 2021.

To be able to confidently supply a volume of product into any market, a legal manufacturer must integrate three primary elements being Manufacturing, Distribution and Quality Management. Any scaled selling of product carries considerable commercial risk if the integration of these elements is not robust. Whilst we recognise that there has been a significant and immediate imperative to turn on sales to support the Life Science business, we have balanced our progression to ensure we also protect long term security of the business. We are now confident that we have progressed these elements to the point that our scaled selling risk is reduced.

1. Manufacturing

Nano technology is a complex science with many variables. Scaling up the technology to produce a product with enough volume to supply a market can be a difficult process due the number of variables that can cause issues. Since April 2021 we have been gradually scaling production at Operon and have resolved issues relating to supplier material variations, batch quality of supplied particle, interface issues between Operon produced product and Axxin produced product. These types of issues are very common in IVD manufacturing, and we often use our close relationships with Operon, Ellume and other manufacturers to discuss issues and share resolution pathways.

It is inevitable that manufacturing will encounter difficulties in the future due to the many variables at play. However, having committed the effort of the last eight months we are now confident that our product can be produced at the scale required to support a large volume of sales.

2. Distribution

Distribution of an IVD product in any country requires a specialist firm to provide logistics, training, customer support, feedback, level 1 & 2 issue resolution and provide information to the manufacturer to support future development. Also scrutinised by regulators and supported under the ISO13485

guidelines, it is important that these elements be established with each distributor. This takes some time and to date we have provided all material and training to existing distributors and continue to work with them to finalise quality procedures.

We will continue to expand our distribution network and we are in the process of continuing to build out our distributor support team under the leadership of Ian Steinhardt.

3. Quality Management

The cornerstone of market operations for a legal manufacturer of an IVD is the Quality Management function. This function provides processes and procedures that underpin all aspects of the business from acquisition of regulatory approval through development and all in-market operations, including manufacturing, distribution, and post-sale activity.

We have invested heavily in this area over the past year as it was a cornerstone element of the transformation of the business from a raw material supplier to a legal manufacturer of an IVD. It has taken time to build the team and establish the systems and processes that will stand up to regulatory scrutiny. Having a baseline level of the Quality Management function in place is mandatory to hedge the commercial risk of failing to deliver a high level of quality.

Whilst we know we need to continue this very important work, we currently have a Quality function that will begin to support scaled market operations.

Sales and Market

At the Annual General Meeting in November, CEO Derek Thomson presented the CY22 Revenue Generation Approach, outlining the four key areas of focus. The Quarter's activities were focused on execution of these areas.



Increasing Market Footprint – Maximise Revenues

Further strengthening our sales and marketing capacities, Ian Steinhardt commenced as Head of Markets on the 6th of December. He brings to the table career experience covering medical research, commercial success in the IVD and Life Science markets covering ANZ, Asia and Europe.

Europe:

In Europe, we have established regular one on one sales meetings with key European distributors to support their domestic initiatives for the EuGeni platform and the development of rolling three-month sales forecasts. Our European representative, Kostas Tzemos, and Ian Steinhardt, have concentrated on aligning the European distributors to focus on available key market segments, Pharmacy, Aged Care, Hospital both in and outside of the Pathology Laboratory market.

We are also working with Exxe, our Italian distributor, to further understand the Italian government's recently announced position on moving to a third-generation Rapid Antigen Test, given the market dynamics and impact of Omicron. In addition, we continue to work with Exxe to identify market opportunities.

During the Quarter, we continued our engagement and search for additional distributors to build our network and partnerships with key leaders within the European IVD space. We have recently commenced initial EuGeni overview discussions with a leading German clinical diagnostics company and are entering into a CDA to enable further discussions.

Australia:

The Omicron wave brought with it significant and welcome change in Australian State and Federal Government stances toward the acceptance and inclusion of RATs as a frontline tool in managing the pandemic, thereby creating new market opportunities.

Over the course of the Quarter, we have engaged with State Government departments presenting the value that the EuGeni solution can deliver. Not only is the quality and performance of the assay (test) critical, but EuGeni has the advantage of facilitating good data management, allowing digital integration.

We have also sought to stimulate manufacturing discussions, making representation at a Federal level to discuss sovereign manufacturing capability to deliver continuity of supply of RATs to the Australian market. These discussions are in the initial stages and ongoing.

We continue to work closely with our distributor, Abacus dx in supporting market development across several markets, covering public and private pathology laboratories, aged care, mining, and workforce management.

Together with Abacus dx, we have made key presentations to leading Point of Care networks managed by public laboratories, with further engagement and evaluations being planned.

Regulatory Approvals

TGA

Our initial TGA application was submitted in September [ASX 23 September 2021] following the external audit and validation of our ISO 13485 certification for Manufacturer of a Medical Device. In December, the TGA contacted AnteoTech to indicate that additional clarification information was required relating to planning for Variants of Concern.

The additional information was compiled and submitted to the TGA in January. Following a review of the additional information, the TGA has requested further clinical data be provided, together with

other aspects of information. At the time of writing, AnteoTech was working through the details of the request with the TGA to determine the expected timeframe needed to gather the additional information and fulfil the conditions of the TGA's guidelines.

European Common List

In 2021 the European Union implemented a regulatory framework, the "Common List", to adopt RATs that would be mutually recognised by all European Union countries primarily for use on the European passport system – EU COVID Digital Passport System.

The Common List framework is entirely independent of the current European In Vitro Diagnostic Regulation (IVDR) soon to be enacted on the May 26, 2022.

The European Common List only exists for COVID-19 RATs. No other rapid test has this regulatory framework.

Recently the EU Common List has been used as a preselection tool by member countries for the use of COVID-19 tests in market segments not connected to the European COVID-19 passport system.

The requirements and process for entry onto the EU Common list changed several times during 2021. Currently, manufacturers of COVID-19 RATs who wish to be included on the EU Common list require sponsorship by an EU member state and a full European based prospective clinical trial including 100 positive samples and 200 negative samples, achieving a sensitivity of 80% or above and specificity of 98% or above.

Opportunities to procure the required member state sponsorship and run an efficient clinical trial in Europe were progressed during the Quarter, although strong competition exists for access to hospitals and clinics to run the trials.

The Italian pharmacy RAT service targeted by AnteoTech's distributor Exxe requires EU Common List registration for participation. We will fulfil this requirement by running a clinical trial in Spain via the Spanish clinical research organisation AKRN.

Production & Quality Optimisation

In anticipation of increased demand, several scaled-up production runs of 100m were completed at Operon during the quarter (up from 25m) to allow manufacturing scalability to maximum capacity when required. We have worked in partnership with Operon to identify several steps that can be optimised during the manufacturing process to secure maximum output. We are now working with Operon to implement these steps to ensure scale-up manufacturing processes are optimal for maximum capacity production runs. Separately, we continued quality testing across product batches with actual samples during the quarter.

The Quality team has worked hard to build systems and processes for scaled-up product delivery during the quarter. We are currently installing an outsourced quality IT system that will automate the many processes required to allow technical transfer and produce high-quality EuGeni products and AnteoBind raw materials. This is an essential step in our journey toward scaled delivery and will complement the ongoing development of quality processes connected to manufacturing.

Manufacturing Equipment

The test strip manufacturing equipment ordered last year is scheduled to arrive in late Q1/early Q2, logistics dependant, following planned factory acceptance testing in early March. The general COVID-19 disruption seen globally across supply chains and manufacturing over the past six months has drawn out the timeline for the receipt of this equipment beyond what was communicated in our last Quarterly Update.

Once the equipment arrives in Brisbane, it will undergo site acceptance testing and commissioning, followed by qualification testing, which includes Installation Qualification, Operation Qualification and training and Performance Qualification, prior to the first test strips running off the line.

Product Development

COVID/ Flu A/B

The multiplex (COVID, Flu A/B) will move to prototype development, with the aim of preparing R&D batches in Feb 2022. In this verification and validation stage, R&D lots will be tested in replicate to determine the uniform performance of the assay. We are currently in discussions with Contract Research Organisations that offer services for analytical performance to support the development by providing validation on analytical sensitivity (Lower limit of detection, LoD of live viruses, TCID50/mL). We expect that laboratory validation will commence in the coming months.

Sepsis Biomarker Tests

The development work on the stand-alone IL-6 and PCT biomarkers from our Sepsis family have completed Phase 0 in the design cycle, with Phase 1 completion targeted for Feb 2022 with lab validation study and performance study in the coming months.

Phase 1 focuses on consistency and reproducibility to meet the product requirements. In addition, the effects of each of the assay components, cassettes, readers, and sample preparation will be investigated. The end goal of this phase is to lock the design and enter the production of prototypes for subsequent clinical testing.

Renewal of AnteoBind contract with Ellume

In November, AnteoTech renewed its contract with leading healthcare diagnostic partner Ellume Ltd. (Ellume) for the supply of AnteoBind to be used in Ellume's range of tests.

AnteoTech and Ellume have been in partnership since 2016, and this contract renewal highlights the strong relationship between the two companies. The new contract is for an additional five-year period, with the terms of the contract commercial-in-confidence. The new contract does reflect the significant transformation both companies have undergone over the past five years and the improved commercial positions of each entity.

A first-order for AnteoBind, under the new contract, was received during the quarter and delivered at the end of December. The income for this sale will be recorded in the next Quarters cash inflows.

Energy

The Energy team is pleased to report on the most recent progress of the AnteoX (cross-linker additive) program targeting increased electrode performance by improving binder chemistries for Lithium-ion battery electrodes.

At the Annual General Meeting in November, CEO Derek Thomson presented the approach to Seizing the Opportunity generated from our advances in application of AnteoX and our work in developing silicon anode reference designs.



Third-Party Evaluation of Silicon Dominant Anodes

During the quarter, the Energy team prepared a number of silicon dominant anodes using the reference design developed to evaluate AnteoX. Discussions with third parties included two battery manufacturers and one technology partner. A fourth organisation, a battery manufacturer, plans to evaluate the anode composition provided by AnteoTech by fabricating and testing it themselves.

Currently, these anodes are being evaluated to determine if the design provided by AnteoTech fits with the organisation's respective technology roadmaps.

This initial engagement with these organisations will hopefully provide the basis for further collaboration and development of the anode program.

AnteoX Program Update

Third-Party Evaluation of AnteoX

External evaluation of AnteoX continued during the quarter. The Energy team prepared samples for five new organisations to be tested in the development of silicon-containing anodes of varying design. The organisations include two Lithium-ion battery manufacturers, one binder company, one technology development partner, and a large chemical company.

As previously reported, different organisations across the Lithium-ion battery value chain will have varying focus points for the evaluation of AnteoX. Some organisations are interested in evaluating AnteoX for high-performance applications with relatively short adoption time frames, and other

partners are positioning their interest around their long-term anode strategies. High-performance applications may have adoption timeframes within two years whereas, automotive OEM's have standard qualification and adoption processes that could span a four to five-year timeframe.

In addition, organisations seek different attributes by adding AnteoX depending on the organisation's anode composition and target silicon content. For example, companies that work on high silicon content anode configurations may want to reduce the total binder content in the anode by cross-linking the underlying base binder, minimising expansion and improving cycle life. Other industry participants working on lower silicon content anode configurations may want to achieve higher coating loadings in weight per unit area to drive up the attainable capacity per electrode whilst maintaining electrochemical performance at the same level.

Early interactions with these organisations are positive. Our continuing program of work focuses on joint testing to optimise AnteoX to achieve desired results and demonstrate various value propositions based on each partner's area of interest and problem sets.

Collaborator Program

Our Collaborator program continues to focus on relationships with Collaborators 2 & 8. As reported in the last Quarterly update, the engagement with these two collaborators is evolving to include customers and partners of the collaborators as we expand our interactions across the Lithium-ion battery value chain.

The discussions around commercialisation pathways with Collaborator 2 and opportunities for a joint product offering with Collaborator 8 are continuing, with engagements progressing positively.

The close and continuously deepening working relationships with Collaborator 2 & 8 has encouraged them to introduce us to their prospective customers and partners, which was in part responsible for the significant increase in sample volumes delivered for evaluation as well as first opportunities to showcase AnteoTech's anode design to key contacts in the industry.

We maintain a close relationship with all other collaborators.

AnteoX and SBR Binder Compatibility Assessment

The AnteoX (cross-linker additive) program targets increased electrode performance by improving properties such as electrode coating cohesion for the application in Lithium-ion batteries. During the Quarter, positive results were realised while conducting preliminary compatibility and stability assessments of AnteoTech's cross-linker additive, AnteoX, with styrene-butadiene rubber (SBR) binders. (SBR is a water-based binder used to prepare anode electrodes for most commercially manufactured Lithium-ion batteries.)

AnteoX, when paired with an SBR binder emulsion in solution, combine to form a stable mixture. The formation of a stable mixture indicates that AnteoX is compatible with SBR binder emulsions and thus is expected to be processable in commercial anode formulations that use SBR binders. This is a result that had previously not been attained when trialling earlier formulations of AnteoX. Further, a cross-linking effect was observed when combining AnteoX with SBR/ carboxymethyl cellulose (CMC) mixtures.

Cross-linked network structures are widely regarded as being key for future binder advancements as they can help improve various performance aspects of the anode coating. Importantly, the stability of the emulsion could allow for the combining of the SBR binder and AnteoX products, enabling commercial opportunities for marketing one single emulsion as opposed to two separate products.

These initial results form part of the first stage of assessing the compatibility of AnteoX when paired with the conventionally used SBR/CMC binder pairing. Further investigations will need to be undertaken to

assess the performance of AnteoX with SBR/CMC as an advanced binder formulation especially when scaled up and processed for inclusion in a full anode coating.

To date, AnteoX has been successfully paired with polyacrylic acid (PAA) binders as part of the development program for the high silicon content anode design, yielding more stable cycling performance and capacity retention [ASX 26 April Energy Collaborator Program Creates Commercialisation Pathway for AnteoX].

It is envisaged that the AnteoX & SBR/CMC program will follow a similar development path, with significant testing and evaluation required to further assess the underlying cross-linking effect and resulting physical changes in the anode as well as its electrochemical properties. A development and testing program focusing on AnteoX & SBR/CMC has not yet been established, and timelines will depend on commercial partners and AnteoTech's resources.

The results explained

CMC/SBR hydrogels with AnteoX

After preparation.

SBR and CMC binder mixtures with varying ratios of AnteoX added.

The mixtures shown are stable, not displaying any cross-linking upon mixing, which is the desirable outcome from a slurry processing perspective.



After heating to 90°C for 6h.

The heat curing effect, which involves heating the mixture to 90°C for 6 hours, achieved the desired effect of a stronger (hard) mixture. Demonstrating **1)** AnteoX can be effectively paired with an SBR binder component forming stable mixtures and **2)** a ternary mixture of SBR/CMC/AnteoX displays a cross-linking effect.

The Global Anode Market

SBR (binder) and CMC dispersing agent have been critical components in anode formulations since the industry's move towards water-based processes. These two components are widely used in conventional graphite-based anodes and graphite and silicon oxide blends, which combined are forecast to make up 80% of the global anode active material market by 2040. The Lithium-ion anode binder market is dominated by SBR binders (paired with CMC), taking up 96% of the market share in 2021.

Should the AnteoX & SBR/CMC program yield positive results, AnteoX has the potential to play a significant role in the performance enhancement of both conventional (2) and silicon dominant anode markets.



Source: Benchmark Mineral Intelligence 2021

The highest value use case for AnteoX is the high silicon content segment and silicon dominant anode designs. **(1)**

A secondary use case for AnteoX is the conventional (natural and synthetic) blended anodes market with low contents of silicon (7-15%), currently using SBR binder and CMC **(2)**

Investor Relations

Annual General Meeting

AnteoTech's AGM was held virtually at 1pm AEST (Brisbane) / 2pm AEDT (Sydney, Melbourne) on Thursday, 11 November 202. Results of the meeting were released to the ASX on 11 November and can be downloaded from the Announcement section of the Company's website.

A recording of the Annual General Meeting and following CEO Presentation can be found on the Investor Centre page https://www.anteotech.com/investors/ or on the Company's **YouTube Channel**

Corporate

R&D Tax Rebate

During the quarter, the Company advised that it had received a cash refund of $1,965,463 under the Federal Government's Research & Development (R&D) Tax Incentive Scheme. The rebate relates to eligible R&D activities conducted by AnteoTech in its Life Science and Energy divisions for the 2021 financial year.

Cash

Cash receipts for the quarter totalled $2,135,000 (includes $1,965,463 R&D tax),

Net cash outflows from operating activities was $0.611 million

The Company remains well funded to support its near term commercial and clinical milestones, including the expansion required for the in-house test strip manufacturing.

AnteoTech had $16.62 million cash on hand as at 31 December 2021 and no debt.

ASX Listing Rule 4.7C disclosure

$99,000 was spent during the quarter to Related Parties, as reported in Item 6.1 of the ASX Appendix 4C (Quarterly Cash Flow Report). This comprises the directors' fees.

For further information, please check our website (www.anteotech.com) or contact Mr Derek Thomson on + 61 7 3219 0085. Media and investor inquiries may also be directed to Friederike Graser, on +61 7 3219 0085.

This announcement has been authorised for release by the Board.

About AnteoTech - AnteoTech Ltd (ASX:ADO)
AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy, and medical devices markets.

AnteoTech - Social Media Policy
AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.
Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Latest News** bulletin, our email alert service.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
AnteoTech Ltd	
ABN	**Quarter ended ("current quarter")**
75 070 028 625	31 December 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	170	305
1.2	Payments for		
	(a) research and development	(520)	(1,030)
	(b) product manufacturing and operating costs	(26)	(358)
	(c) advertising and marketing	(150)	(289)
	(d) leased assets	(102)	(191)
	(e) staff costs	(1,526)	(2,530)
	(f) administration and corporate costs	(422)	(833)
1.3	Dividends received (see note 3)		
1.4	Interest received	0	1
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives	1,965	1,965
1.8	Other (ATO cash boost)		
1.9	**Net cash from / (used in) operating activities**	**(611)**	**(2,960)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	(1,382)	(2,042)
	(d) investments		
	(e) intellectual property	(79)	(117)
	(f) other non-current assets		

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**(1,461)**	**(2,159)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	338	343
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	**Net cash from / (used in) financing activities**	**338**	**343**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	18,350	21,392
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(611)	(2,960)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,461)	(2,159)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	338	343
4.5	Effect of movement in exchange rates on cash held		
4.6	**Cash and cash equivalents at end of period**	**16,616**	**16,616**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	16,616	18,350
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**16,616**	**18,350**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	99
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	2,576
8.2	Cash and cash equivalents at quarter end (item 4.6)	16,616
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	16,616
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	6.5

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

By the Board
Tim Pritchard
Company Secretary
31 January 2022

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.